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Abstract
Background: Genomic DNA amplification is a genetic factor involved in cancer, and some oncogenes, such as
ERBB2, are highly amplified in gastric cancer. We searched for the possible amplification of other genes in
gastric cancer.
Methods and Results: A genome-wide single nucleotide polymorphism microarray analysis was performed
using three cell lines of differentiated gastric cancers, and 22 genes (including ERBB2) in five highly amplified
chromosome regions (with a copy number of more than 6) were identified. Particular attention was paid to the
CRKL gene, the product of which is an adaptor protein containing Src homology 2 and 3 (SH2/SH3) domains.
An extremely high CRKL copy number was confirmed in the MKN74 gastric cancer cell line using fluorescence in situ
hybridization (FISH), and a high level of CRKL expression was also observed in the cells. The RNA-interference-
mediated knockdown of CRKL in MKN74 disclosed the ability of CRKL to upregulate gastric cell proliferation.
An immunohistochemical analysis revealed that CRKL protein was overexpressed in 24.4% (88/360) of the primary
gastric cancers that were analyzed. The CRKL copy number was also examined in 360 primary gastric cancers using
a FISH analysis, and CRKL amplification was found to be associated with CRKL overexpression. Finally, we showed
that MKN74 cells with CRKL amplification were responsive to the dual Src/BCR-ABL kinase inhibitor BMS354825,
likely via the inhibition of CRKL phosphorylation, and that the proliferation of MKN74 cells was suppressed by
treatment with a CRKL-targeting peptide.
Conclusion: These results suggested that CRKL protein is overexpressed in a subset of gastric cancers and is
associated with CRKL amplification in gastric cancer. Furthermore, our results suggested that CRKL protein has
the ability to regulate gastric cell proliferation and has the potential to serve as a molecular therapy target for
gastric cancer.
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Background
Although the overall incidence of gastric cancer is de-
creasing in many countries, the high incidence of gastric
cancer remains a serious health problem, and gastric can-
cer continues to be the second-leading cause of cancer-
related death worldwide [1,2]. Gastric carcinogenesis is
a multi-step process in which environmental and genetic
factors interact [1–8]. Among the genetic changes observed
in cancerous cells, genomic DNA amplification is a well-
known alteration that is involved in gastric cancer [4,5,7].
Amplification is often associated with increased expres-
sion levels of the genes contained in the amplified loci
[5]. Oncogenes in gastric cancer, such as MYC (mapped
to chromosome 8q24), KRAS (12p12), and ERBB2
(17q12), are located in such amplified regions [4,5,7,9].
We considered the possibility that there exist genes
whose amplification in gastric cancer has not been
revealed to date. To uncover such novel gene
alterations, we searched for highly amplified genes in
* Correspondence: hsugimur@hama-med.ac.jp
1Department of Tumor Pathology, Hamamatsu University School of Medicine,
1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka 431-3192, Japan
Full list of author information is available at the end of the article
© 2012 Natsume et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Natsume et al. Journal of Translational Medicine 2012, 10:97
http://www.translational-medicine.com/content/10/1/97gastric cancer using a genome-wide single nucleotide
polymorphism (SNP) microarray analysis and found that
the CRKL [v-crk sarcoma virus CT10 oncogene homolog
(avian)-like] gene (22q11) is highly amplified in gastric
cancer. The CRKL, a member of the CRK family of
adapter proteins, consists of an NH2-terminal Src hom-
ology 2 (SH2) domain followed by two SH3 domains:
SH3n and SH3c [10], and participates in signal transduc-
tion in response to growth factors, cytokines, and the
oncogenic BCR-ABL fusion protein, resulting in cell prolif-
eration, survival, adhesion, and migration [10,11]. We
hypothesized that CRKL might play an important role in
gastric carcinogenesis and investigated whether CRKL ex-
pression and the function of CRKL protein affect the regu-
lation of cell proliferation in gastric cancer. We also
investigated responsiveness of a gastric cancer cell line
containing CRKL amplification to a kinase inhibitor,
BMS354825, and a CRKL-targeting peptide.
Materials and Methods
Cell lines and surgical specimens
The gastric adenocarcinoma cell lines MKN7, MKN28,
MKN74, and AGS were purchased from the Human
Science Research Resource Bank (Osaka, Japan) or from
American Type Culture Collection (Manassas, VA). Cells
were cultured and grown in RPMI 1640 medium supple-
mented with 10% fetal bovine serum, penicillin (100 units/
mL), and streptomycin (100 μg/mL) under a 5% CO2
atmosphere at 37°C. Paraffin-embedded gastric tissues
obtained from gastric cancer patients who underwent
surgery at Toyohashi Municipal Hospital (Japan) were
used for the immunohistochemical analysis. Gastric tissue
samples obtained from gastric cancer patients who under-
went surgery at Hamamatsu University Hospital (Japan)
were used for the quantitative reverse-transcription (QRT)-
polymerase chain reaction (PCR) analysis. The study design
was approved by the Institutional Review Boards (IRBs).
Genome-wide SNP microarray
DNA (250 ng) was digested with NspI restriction enzyme
(New England Biolabs, Hertfordshire, UK) and ligated to
a universal adaptor sequence. The ligated DNA was
PCR-amplified using primers complementary to the
universal adaptors, and the PCR products were purified,
quantified, and normalized. The products were then frag-
mented, end-labeled using terminal deoxynucleotidyl
transferase, and hybridized to the Affymetrix GeneChip
human mapping 250 K NspI arrays (Affymetrix Japan,
Tokyo, Japan). After hybridization, the arrays were
washed, stained using Affymetrix fluidics station 450, and
scanned with a GeneChip Scanner 3000 7 G. Raw SNP
call data were extracted using Affymetrix GeneChip
Genotyping Analysis software (GTYPE) 4.1. The SNP
microarray data were analyzed to determine the total
copy number using the CNAG program, as previously
described [12,13] (Figure 1).
WST-8 assay
Cell proliferation and viability were quantified using a
Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) accord-
ing to the manufacturer’s instructions [14]. The assay
was based on the extracellular reduction of the tetrazo-
lium salt WST-8 by NADH produced in the mitochon-
dria of living cells. The cells were incubated with the
WST-8 reagent for 1 hr at 37°C, and the absorbance was
measured at 450 nm using an EL340I microplate reader
(BIO-TEK Instruments, Winooski, VT) (Figure 2).
Immunohistochemistry
Tissue microarray (TMA) blocks were prepared as pre-
viously described [14-16]. TMA block sections were
deparaffinized, rehydrated, and boiled in Tris-EDTA
buffer (pH 9.0) for antigen retrieval. Endogenous perox-
idase activity was blocked by incubation in a hydrogen
peroxide solution. Next, the sections were incubated
with a rabbit anti-CRKL monoclonal antibody (Y243;
Abcam, Cambridge, UK). The antigen-antibody complex
was visualized using Histofine Simple Stain Max-Po
(Multi) (Nichirei, Tokyo, Japan) and 3,3'-diaminobenzidine
tetrahydrochloride. Counterstaining was performed using
hematoxylin. The intensity values of the cells were deter-
mined using a 4-point scale according to the color of the
cell cytoplasm after CRKL immunostaining as follows:
0, blue; 1, blue-brown; 2, light brown; and 3, brown. The
percentage of cells with each intensity value was then
multiplied by the intensity value, as described previously
[14]. The scores obtained for CRKL immunostaining
were classified as either a low expression level (0–0.99)
or a high expression level (1.00–3.00) (Figure 3).
DNA fluorescence in situ hybridization (FISH)
FISH was performed as previously described [16-19].
Tissue slides were hybridized with a Spectrum Orange-
labeled BAC clone (RP11-801O20 and RP11-1058B20)
for the CRKL locus (Advanced GenoTechs Co., Tsukuba,
Japan) and a Spectrum Green-labeled control probe for
the near centromere locus on chromosome 22 (BAC
clone: RP11-232E17). 4',6-Diamidino-2-phenylindole
(DAPI) (Vector Laboratories, Burlingame, CA) was used
for nuclear staining (Figure 3).
MTT assay and direct cell counting
In the experiment involving treatment with the CRKL-
targeting peptide, an MTT assay was performed to assess
cell viability in Figure 4G. The cells were cultured with
the indicated concentration of CRKL-targeting peptide
or dimethyl sulfoxide (DMSO) at 37°C for 72 h,
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
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gastric cancer. (A) Genome-wide detection of copy number alterations using a high-density SNP microarray in the MKN74 gastric cancer cell
line. The copy number status for the whole genome of MKN74 is shown. DNA (250 ng) was analyzed using an Affymetrix GeneChip 250 K NspI
array, and the total copy numbers were determined by analyzing the microarray data using the CNAG program. The chromosome number is
shown above the panel. Chromosome 22 is highlighted in red. (B) The copy number status of chromosome 22 of the MKN74 cells is shown.
A highly amplified region of chromosome 22 is enlarged, and the genes located in this region are indicated. The CRKL gene is highlighted in red.
(C) Detection of CRKL amplification in MKN74 cells using a FISH analysis. The left panel shows the CRKL signal (red) in MKN74 cells, while the
right panel shows the CRKL (red) in non-cancerous gastric tissue cells. An extreme increase in the CRKL copy number was observed in the
MKN74 cells, while a normal copy number (2) was seen in non-cancerous cells. Nuclei are stained with DAPI. (D) Detection of the increased
expression of CRKL mRNA transcript in MKN74 cells using real-time QRT-PCR analysis. The amounts of CRKL transcripts normalized to the amount
of GAPDH transcripts are shown in the graph. The average expression level of eight normal gastric mucosa samples was measured as a control.
(E) Detection of the increased expression of CRKL protein in MKN74 cells using a western blot analysis. The expression of CRKL was examined
using anti-CRKL monoclonal antibody (Y244; 1:500 dilution), horseradish peroxidase-coupled secondary antibody (1:5,000 dilution), and enhanced
chemiluminescence detection reagents. The expression of β-tubulin protein was analyzed as an internal control.
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was then added at a final concentration of 0.25 mg/mL.
After incubation at 37°C for 4 h, absorbance was mea-
sured at a wavelength of 570 nm using a microplate
reader. Cells grown in complete medium with DMSO
alone were used as controls. The final concentration of
DMSO was set to 0.2%. To assess cell proliferation in
Figure 4H, the cells were cultured with CRKL targeting
peptide or DMSO at 37°C for 72 h. Cell proliferation was
measured by directly counting the cells using a
hemocytometer, as described previously [20].
QRT-PCR
Total RNA was extracted using Isogen (Nippongene,
Tokyo, Japan) or an RNeasy Plus mini kit (Qiagen,
Valencia, CA) and converted to cDNA using the Super-
Script First-Strand Synthesis System (Invitrogen, Carlsbad,
CA). Real-time QRT-PCR was performed using the cDNA
and Fast SYBR Green Master Mix (Applied Biosystems,
Foster City, CA) on a StepOne Real-Time PCR system
(Applied Biosystems). The following PCR primers were
used: 5'-CAA CCT GCC TAC AGC AGA AGA TAA-3'
and 5'-CGG CAT CAT TCC CAG GAA-3' for the CRKL
transcript, and 5'-GGT GGT CTC CTC TGA CTT CAA
CA-3' and 5'-GTT GCT GTA GCC AAA TTC GTT GT-
3' for the transcript of a housekeeping gene, GAPDH.T h e
relative amounts of CRKL transcript were normalized to
those of the GAPDH transcript.
Western blot analysis
Cells were lysed, and the protein concentration was quan-
tified using a BCA protein assay kit (Pierce, Rockford, IL).
The proteins were electrophoresed and transferred to a
PVDF membrane (GE Healthcare Bio Science, Piscataway,
NJ). After blocking with non-fat milk or Blocking One-P
(Nakalai Tesque, Kyoto, Japan), the membrane was incu-
bated with rabbit anti-CRKL monoclonal antibody (Y244;
Abcam), rabbit anti-phospho CRKL polyclonal antibody
(Y207; Cell Signaling, Beverly, MA), or mouse anti-β-
tubulin (2-28-33, Sigma-Aldrich). The immunoreactive
proteins were visualized using horseradish peroxidase-
coupled secondary antibody and enhanced chemilumines-
cence detection reagents (GE Healthcare Bio Science) [21].
Small interfering RNA (siRNA) knockdown
A stealth siRNA duplex oligonucleotide (Invitrogen)
was used for siRNA knockdown. The following CRKL se-
quence was used: 5'-UCG UGA AAG UCA CAA GGA
UGA AUA U-3'. A low GC Duplex #2 (Invitrogen) was
used as a negative control. MKN74 cells were reverse-
transfected with the siRNA oligonucleotides (20 nM)
using HiPerFect Transfection Reagent (Qiagen), accord-
ing to the manufacturer’s instructions.
BMS354825 and AMN107 treatment
BMS354825, a dual Src/BCR-ABL kinase inhibitor, was
kindly provided by Bristol-Myers Squibb (New York, NY),
and AMN107, a highly selective BCR-ABL kinase inhibi-
tor, was kindly provided by Novartis Pharmaceuticals
(Basel, Switzerland) [22-25]. Stock solutions (10 mM) of
BMS354825 and AMN107 were prepared in DMSO.
The cells were incubated with BMS354825 or AMN107 at
a final concentration of 0.01 to 1.0 μM for 72 h. The final
concentration of DMSO was set to 0.1%.
Figure 2 Ability of CRKL to regulate cell proliferation in the MKN74 gastric cancer cell line. (A) siRNA knockdown for CRKL in MKN74
cells with CRKL amplification. Cells were reverse-transfected with the siRNA oligonucleotides (20 nM) using HiPerFect Transfection Reagent,
and 8×10
5 cells were seeded in 60 mm-dishes with 4 ml media. The expression of CRKL was examined 4 days after the reverse transfection of
CRKL siRNA or negative control siRNA using a western blot analysis with anti-CRKL monoclonal antibody (Y244; 1:500 dilution). The level of CRKL
protein expression was decreased in CRKL siRNA-transfected cells, compared with mock-transfected cells. The expression of β-tubulin protein was
analyzed as an internal control. (B) Decrease in the proliferation of MKN74 cells transfected with siRNA for CRKL. Cells were reverse-transfected
with the siRNA oligonucleotides (20 nM), and 1.5×10
4 cells were seeded in 96-well microplates containing 100 μL of media. After the reverse
transfection of CRKL siRNA or negative control siRNA, the number of viable cells was counted by measuring the reduction in the tetrazolium
monosodium salt WST-8. The cell number of CRKL siRNA-transfected cells relative to that of mock-transfected cells is shown. Values are the
mean±standard deviation of three independent experiments. P-values were calculated using the t-test, and * indicates a statistical significance.
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In this study, we used the peptides, which has been
reported to be disrupted complexes between BCR-ABL
and CRKL depend on the SH3 domain of CRKL in CML
cells [26]. Peptides used in the experiments are followed:
CRKL-targeting peptide; KKW KMR RNP FWI KIQ RC
– CGI RVV DNS PPP ALP PKR RRS APS PTR V, con-
trol peptide; KKW KMR RNP FWI KIQ RC – CGI RVV
DNS PPG ALG PLL RRS APS PTR V. The KKW KMR
RNP FWI KIQ RC was the shuttle tag sequence perform-
ing a receptor-independent cell entry. The chimeric pep-
tide was synthesized and purified by using reverse-phase
high performance liquid chromatography (HPLC) (Toray
Research Center, Otsu, Japan). Peptide stocks were pre-
pared in DMSO and stored in aliquots at -80°C.
Statistical analysis
The statistical analysis was performed using an unpaired
t-test, chi-square test, or Dunnett’s test. JMP version
7.0.1 software (SAS Institute, Cary, NC) was used for the
analyses. P values less than 0.05 were considered statisti-
cally significant.
Results
Identification of CRKL amplification in gastric cancer
To search for highly amplified genes in gastric adenocar-
cinoma, we adopted a genome-wide high-resolution SNP
microarray approach in three cell lines of differentiated
gastric adenocarcinoma: MKN7, MKN28, and MKN74.
Genotype calls were obtained at more than 95% of the
262,264 SNP sites on the array, meaning that the SNP
microarray analysis had been performed properly. The
SNP microarray data were then used to determine the
chromosomal copy number using the CNAG program
(Figures 1A and 1B). Five highly amplified regions with a
copy number of more than 6 (9p13, 17q12-q21, 19q12,
19q13, and 22q11) were identified, as shown in Table 1.
These regions contained various kinds of genes, a total
of 22 genes (Table 1). Among them, we decided to focus
on the CRKL gene at chromosome 22q11.21, the product
Figure 3 Immunohistochemical detection of CRKL protein in primary gastric cancer. TMA block sections were subjected to an
immunohistochemical analysis using anti-CRKL monoclonal antibody (Y243; 1:100 dilution), Histofine Simple Stain Max-Po (Multi), and
3,3'-diaminobenzidine tetrahydrochloride. Intensity values of 0, 1, 2, and 3 are shown in (A), (B), (C), and (D), respectively. Bar=50 μm.
(E) Box-plot analysis of CRKL protein expression in gastric tissue. A statistically significant difference in the CRKL expression level was detected
between non-cancerous gastric foveolar epithelium (n=41) and gastric cancerous tissue (n=360). (F) Representative result of the CRKL
immunohistochemical analysis. A gastric cancer with a high CRKL expression level is shown. Bar=500 μm. The inset is a magnified image.
Bar=50 μm. (G) Representative gastric cancer case showing both a high CRKL expression level and CRKL gene amplification. The high CRKL
expression level (value=2.6) was detected using an immunohistochemical analysis. Bar=100 μm. The inset shows the amplification of CRKL (red)
in the cancer cells. The CRKL signal (red) and the control signal for chromosome 22 (green) were detected using a FISH analysis. Nuclei are
stained with DAPI.
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adaptor protein that shares homology with the CRK
oncoprotein, because CRKL is a known substrate of
BCR-ABL kinase in Philadelphia chromosome-positive
leukemia [27,28] and its role in gastric cancer has not
been previously analyzed. To confirm that CRKL gene
amplification was detectable in the MKN74 cell line, we
performed a FISH analysis using a probe specific for
CRKL. As expected, an extreme increase in the CRKL
copy number was detected in the MKN74 cells using a
FISH analysis (Figure 1C). When the level of CRKL
mRNA expression was examined in MKN74 cells using
a real-time QRT-PCR analysis, the level was much
higher than that in non-cancerous gastric tissue (Fig-
ure 1D). Moreover, a western blot analysis showed that
the level of CRKL protein expression was higher in
MKN74 cells than in non-cancerous gastric tissue (Fig-
ure 1E). These results suggested that the CRKL gene is
highly amplified and that CRKL is overexpressed in a
subset of gastric cancer cell lines.
Figure 4 (See legend on next page)
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To explore the functional significance of CRKL amplifi-
cation in gastric cancer, we attempted to examine the
effect of overexpressed CRKL on gastric cell prolifera-
tion. For this purpose, we prepared MKN74 cells with
distinct CRKL expression levels using the siRNA knock-
down of CRKL expression. CRKL-specific siRNA trans-
fection effectively decreased the level of CRKL protein
expression in MKN74 cells by approximately 70% of the
levels observed in negative control siRNA-transfected
cells (Figure 2A). A cell proliferation assay showed that
the number of CRKL siRNA-transfected MKN74 cells
was significantly lower at 3 and 4 days after transfection
than the number of negative control siRNA-transfected
cells (Figure 2B), meaning that CRKL has the ability to
upregulate cell proliferation.
Overexpression of CRKL protein in gastric cancer
Next, we investigated the expression status of CRKL pro-
tein in primary gastric cancer using an immunohisto-
chemical analysis with anti-CRKL monoclonal antibody
(Y243). CRKL was mainly observed in the cytoplasm,
consistent with previous reports [29]. When we compared
the level of CRKL expression between non-cancerous gas-
tric foveolar epithelium (n=41) and gastric cancer
(n=360), the level of CRKL expression in gastric cancer
(mean±standard deviation=0.42±0.63) was significantly
higher than that in non-cancerous tissue (0.20±0.26)
(P=0.032) (Figures 3A-3E). When an expression level
of 1.00, which corresponds to a value 5-fold of the mean
expression level in non-cancerous gastric foveolar epi-
thelium, was used as a cutoff value for the expression
status in gastric cancer (i.e., low expression group, 0–0.99;
high expression group, 1.00–3.00), 88 (24.4%) of the 360
primary gastric cancers were included in the high expres-
sion group (Figure 3F). To examine whether CRKL overex-
pression is associated with CRKL amplification in gastric
cancer, we performed a FISH analysis for the CRKL gene
in the 360 primary gastric cancers and compared
t h ep r e v a l e n c eo fCRKL amplification between the low
expression group and the high expression group. As
Table 1 Detection of chromosomal regions with a high
copy number (more than 6) in the gastric cancer cell lines
MKN7, MKN28, and MKN74 using a genome-wide SNP
microarray analysis
Chromosomal
regions
a
Genes with a high copy number in the region
9p13 PAX5
17q12-q21 FBXL20, MED1, PERLD1, ERBB2, IKZF3, ZPBP2
19q12 CCNE1
19q13 CD22
22q11 DGCR8, USP41, ZNF74, SCARF2, KLHL22, MED15, PI4KA,
SERPIND1, SNAP29, CRKL, THAP7, P2RX6, LOC729526
a If more than four consecutive SNP probes with a copy number of more
than six were detected in either of the three cell lines, the chromosomal
region was regarded as being a “highly amplified region” and was listed in this
table.
(See figure on previous page)
Figure 4 Responses of the MKN74 gastric cancer cell line with CRKL amplification to treatment with BMS354825 (a dual Src/BCR-ABL
kinase inhibitor) and CRKL-targeting peptide. (A) Viability of MKN74 cells treated with BMS354825 but not those treated with AMN107
(a highly selective BCR-ABL kinase inhibitor) is decreased. The cells were seeded in 96-well microplates at a density of 1×10
4 per well; after 24 h,
the drug (0.01–1.0 μM) or 0.1% DMSO solution was added. Viability was examined in the MKN74 cells after 72 h of treatment at the indicated
concentration using WST-8 reagent. The number of viable cells after treatment with each inhibitor was normalized to the number of viable cells
without treatment, and the relative viability is shown in the graph. Values are the mean±standard error. P values were calculated using the
Dunnett’s multiple comparison test, and * indicates a statistically significant decrease. (B) Effective inhibition of CRKL phosphorylation in MKN74
cells treated with BMS354825. Cells were treated with each inhibitor (DMSO only or 0.01 μM of drug) for 90 min, and the expression of CRKL
protein was examined using a western blot analysis with anti-phospho CRKL polyclonal antibody (Y207; 1:1,000 dilution) or anti-CRKL monoclonal
antibody (Y244; 1:500 dilution). The expression of β-tubulin protein was analyzed as an internal control. (C) Comparison of CRKL mRNA transcripts
between AGS and MKN74 cells using real-time QRT-PCR analysis. The amounts of CRKL transcripts normalized to the amount of GAPDH
transcripts are shown in the graph. (D) Comparison of expression of CRKL protein between AGS and MKN74 cells using a western blot analysis.
The expression of CRKL was examined using the primary antibodies shown in (B). The expression of β-tubulin protein was analyzed as an
internal control. (E) Detection of CRKL gene copy number in AGS cells using a FISH analysis. The CRKL signal is red, and the control signal for
chromosome 22 is green. Nuclei are stained with DAPI. (F) Viability of AGS cells decreased after BMS354825 treatment. Viability was examined as
described in (A). Values are the mean±standard error. P values were calculated using a t-test, and * indicates a statistically significant decrease.
(G) MKN74 cells with CRKL amplification and AGS cells without CRKL amplification were seeded in 96-well microplates at a density of 1 × 10
4 per
well. 24 h after seeding, cells were treated with CRKL-targeting peptide (0.0925–25 μM) or 0.2% DMSO solution at the indicated concentration.
The sequence of the CRKL-targeting peptide that was used is shown above the graph. After 72 h of incubation, viability was determined using
an MTT assay. The results are presented as the mean±standard deviation of three independent experiments. P values were calculated using
a t-test, and * indicates a statistically significant difference between the cells treated with CRKL-targeting peptide and those treated with DMSO.
(H) Cell proliferation of MKN74 and AGS cells treated with CRKL-targeting peptide (6.25 μM) or DMSO as measured by counting cells using a
hemocytometer. Cells (1 × 10
4) were seeded in 24-well plates and treated with CRKL-targeting peptide or DMSO. The cell counting was
performed every 24 h for 3 days. Data are shown as the mean±standard deviation of three independent experiments. P values were calculated
using a t-test, and * indicates a statistically significant difference between the cells treated with CRKL-targeting peptide and those treated
with DMSO.
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amplification was significantly higher in the high expres-
sion group (9.1%; 8/88 cases) than in the low expression
group (2.2%; 6/272 cases) (P=0.028, chi-square test). This
result suggests that CRKL amplification contributes to
CRKL overexpression in primary gastric cancer. We further
investigated whether the levels of CRKL expression
is associated with clinicopathological features in primary
gastric cancer patients, the high CRKL expression was
observed significantly more often in male and differen-
tiated-type gastric cancer (Table 2). These results suggested
that CRKL protein is overexpressed partly due to CRKL
amplification in a subset of primary gastric cancers and is
associated with the gender and histopathology.
Decrease in the viability of CRKL-expressing MKN74 cells
treated with BMS354825
Finally, we tested the possibility of using CRKL as a
therapeutic target in MKN74 cells with CRKL amplifica-
tion. Since Philadelphia chromosome-positive leukemia
expressing BCR-ABL is responsive to BMS354825 (a dual
Src/BCR-ABL kinase inhibitor) and AMN107 (a highly
selective BCR-ABL kinase inhibitor) [22,24], we checked
the response of MKN74 cells to both inhibitors. Cell via-
bility was significantly decreased in BMS354825-treated
(0.01–1.0 μM) MKN74 cells, compared with cells treated
with the solvent only, while it was not significantly
decreased in AMN107-treated cells (Figure 4A). When
the status of CRKL phosphorylation was examined in the
MKN74 cells using western blot analysis with an anti-
phospho CRKL antibody, CRKL phosphorylation was
found to be inhibited more effectively by BMS354825
than by AMN107 (Figure 4B). These results suggested
that BMS354825 has the potential to suppress the viabil-
ity of MKN74 cells expressing CRKL, likely via the inhi-
bition of CRKL phosphorylation.
To further characterize the role of CRKL in the
BMS354825-induced suppression of MKN74 cell viabil-
ity, we examined the effect of BMS354825 on gastric
cancer cells without CRKL amplification. Since the
AGS gastric cancer cell line had lower CRKL mRNA and
CRKL protein expression levels than MKN74 cells (Fig-
ures 4C and D) and had a normal CRKL genomic copy
number (Figure 4E), these cells were treated with
BMS354825. Unexpectedly, the viability of the BMS354825-
treated (0.1–1.0 μM) AGS cells decreased significantly
(Figure 4F). Moreover, although the IC50 value (inhibitory
concentration producing a 50% response) for BMS354825
was slightly higher in AGS cells than in MKN74 cells,
the values were not much different between AGS and
MKN74 cells (data not shown). These results suggest that
BMS354825 has the potential to suppress the viability of
AGS cells, likely via a CRKL-independent pathway.
Decrease in the viability/proliferation of CRKL-expressing
MKN74 cells treated with a CRKL-targeting peptide
We then planned to use a more specific inhibitor of
CRKL and examined the response of MKN74 and AGS
cells to a CRKL-targeting peptide [26]. Cell viability
decreased significantly in MKN74 cells treated with the
CRKL-targeting peptide (6.25–25 μM), compared with
DMSO (solvent)-treated cells, but a similar decrease was
not found in AGS gastric cancer cells without CRKL
amplification (Figure 4G). When cell proliferation was
compared after treatment with 6.25 μM of the CRKL-tar-
geting peptide, the cell proliferation was significantly
suppressed in MKN74 cells treated with the peptide,
compared with DMSO-treated MKN74 cells, but no
inhibition of cell proliferation was seen in the AGS cells
(Figure 4H). Control peptide had no effect on the gastric
cancer cell proliferation. These results suggested that the
CRKL-targeting peptide has the potential to suppress the
viability/proliferation of gastric cells exhibiting CRKL
amplification, but not of gastric cells that do not exhibit
CRKL amplification.
Discussion
Through a genome-wide SNP microarray analysis per-
formed in this study, the CRKL gene was identified as a
highly amplified gene in gastric cancer. An increase in
the copy number was confirmed in MKN74 gastric can-
cer cells with CRKL amplification using a FISH analysis,
and a high CRKL expression level was also observed in
these cells. The ability of CRKL to upregulate cell pro-
liferation was shown in MKN74 cells by comparing the
cell proliferation rate between CRKL siRNA-transfected
cells and negative control siRNA-transfected cells. CRKL
Table 2 Association between CRKL expression and
clinicopathological factors in 360 patients with primary
gastric cancer
CRKL expression level
Factor Patient Low (n=272) High (n=88) P
Age
Year, mean±SD
a 62.0±11.2 61.7±11.7 62.9±11.4 0.3936
b
(range) (29–86) (29–86) (31–85)
Gender
Male 255 182 (66.9%) 73 (83.0%) 0.0028
c
Female 105 90 (33.1%) 15 (17.0%)
Histological type
Differentiated 172 118 (43.4%) 54 (61.4%) 0.0033
c
Undifferentiated 188 154 (56.6%) 34 (38.6%)
pT stage
pT1 143 103 (37.9%) 40 (45.5%) 0.2082
c
pT2-pT4 217 169 (62.1%) 48 (54.5%)
a SD, standard deviation.
b t-test.
c Chi-square test.
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gastric cancers, and its level in the gastric cancer was
associated with the gender and histopathology. CRKL
amplification was more frequently found in primary
gastric cancers with high CRKL protein expression levels
than in those with low CRKL expression levels. Finally,
we showed that MKN74 cells with CRKL amplification
were responsive to the kinase inhibitor BMS354825,
likely via the inhibition of CRKL phosphorylation, and
a CRKL-targeting peptide. Our current findings suggest
that CRKL has an important role in the development
of a subset of gastric cancers and has the potential to be
a molecular therapy target for gastric cancer.
CRKL is an adaptor cell signaling protein that con-
tains an SH2 domain and two tandem SH3 domains,
both of which mediate protein-protein interactions
[27,28,30]. CRKL is well known as a surrogate substrate
of BCR-ABL kinase in chronic myeloid leukemia and
acute lymphoblastic leukemia [11,27,28], and intensive
studies of CRKL in Philadelphia chromosome-positive
leukemia have been performed. However, only one
paper by Kim et al. [31] has reported the CRKL status
in gastric cancer. They revealed that the expression of
CRKL mRNA in a cancer cell line was stimulated by
proteins released by Helicobacter pylori, although the
underlying mechanism was not resolved and the CRKL
genomic copy number was not analyzed. Our genome-
wide SNP microarray analysis successfully revealed, for
the first time, that the CRKL gene is highly amplified in
a subset of gastric cancers. We also showed that the
CRKL protein can upregulate cell proliferation using
the RNA-interference-mediated knockdown of CRKL in
a gastric cancer cell line with CRKL amplification.
Thus, CRKL overexpression arising from genomic ampli-
fication likely contributes to the aggressiveness of gas-
tric cancer.
Recent progress in the development of molecular cancer
therapy has revealed new molecular-targeting drugs,
such as EGFR-targeting drug ZD1839 (Iressa) and HER2-
targeting anti-HER2 monoclonal antibody trastuzumab
(Herceptin), to be potent therapies for specific cancers
[32-34]. In this study, BMS354825, a dual inhibitor for
Src and BCR-ABL kinases, but not AMN107, a BCR-
ABL specific inhibitor, showed an inhibitory effect on
the survival of MKN74 cells with CRKL amplification.
A decrease in CRKL phosphorylation through the inhi-
bition of a currently unknown Src kinase seems to be
one of the main mechanisms of BMS354825-mediated
cytotoxicity in MKN74 cells. BMS354825 is currently
being studied clinically in colorectal cancer, prostate
cancer, breast cancer, lung cancer, and Philadelphia
chromosome-positive leukemia [22,23,35]. Our results
suggest that the CRKL protein may be a target of
BMS354825-mediated therapy for a subset of gastric
cancers. In our analyses, BMS354825 suppressed the
viability of AGS cells without CRKL amplification as
well as the viability of MKN74 cells with CRKL amplifica-
tion, suggesting that a CRKL-independent pathway,
which has been previously implicated [36], may also be
involved in the BMS354825-mediated cytotoxicity seen in
gastric cancers. We also presented the usefulness of
a CRKL-targeting peptide for suppressing the prolif-
eration of MKN74 cells with CRKL amplification. Our
results should contribute to the establishment of CRKL-
targeting therapy for a subset of gastric cancers in
the future.
In the present study, a genome-wide, high-resolution
SNP microarray analysis was successfully performed
and five highly amplified chromosome regions contain-
ing 22 genes were identified in gastric cancers, as listed
in Table 1. Although the ERBB2 gene, a well-known
oncogene that is often amplified in gastric cancer [4],
was included in this list, the roles of the most of the
genes in the Table have not been studied in gastric
cancer. Further investigation of these roles is needed in
the future.
Conclusion
We conclude that CRKL protein is overexpressed in a
subset of gastric cancers and is associated with CRKL
amplification in gastric cancer. Furthermore, we con-
clude that CRKL protein has the ability to regulate gas-
tric cell proliferation and has the potential to serve as a
molecular therapy target for gastric cancer.
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